logo

Emergent Biosolutions Inc (EBS)



Trade EBS now with
  Date
  Headline
7/14/2017 7:03:39 AM Emergent BioSolutions To Acquire ACAM2000 Business Of Sanofi In All-cash Transaction With Total Value Of Up To $125 Mln
3/31/2017 7:08:14 AM Emergent BioSolutions Signs $53 Mln Modification To BARDA Contract For The Manufacture Of Botulism Antitoxin
3/17/2017 7:03:33 AM Emergent BioSolutions Bags $100 Mln BARDA Contract For BioThrax Deliveries To Strategic National Stockpile
2/13/2017 7:05:48 AM Emergent BioSolutions Gets BARDA Task Order Valued At Up To $30.5 Mln To Develop Viral Hemorrhagic Fever Therapeutics
2/1/2017 7:15:26 AM Emergent BioSolutions Begins NIAID-Funded Phase 1b Clinical Study To Evaluate Broad-Spectrum Antiviral UV-4B For Dengue
1/27/2017 7:02:09 AM Emergent Gets German Federal Ministry Of Health Approval Of Building 55 For Large-Scale Manufacturing Of BioThrax
1/9/2017 7:09:28 AM Emergent BioSolutions Expects FY16 Revenues Of $500 Mln-$505 Mln, Net Income Of $44 Mln-$48 Mln, On Combined Basis
12/12/2016 7:06:47 AM Emergent BioSolutions Gets Health Canada Approval For Botulism Antitoxin
9/30/2016 9:32:25 AM Emergent Provides Update On The Status Of Its 2011 BioThrax Procurement Contract
9/30/2016 9:06:55 AM Emergent Signs Multi-year Contract Valued At Up To $1.6 Bln With BARDA For Advanced Development, Delivery Of NuThrax
8/21/2016 7:12:15 AM Law Firm Brower Piven Files Class Action Lawsuit Against Emergent BioSolutions
8/10/2016 7:08:24 AM CDC Exercises Contract Option Valued At $11.6 Mln To Further Support Emergent BioSolutions’ Vaccinia Immune Globulin
8/1/2016 7:04:50 AM Aptevo Therapeutics Completes Separation From Emergent BioSolutions